Would you also bring in an investor in PCR Investments (a promoter firm of AHEL)?
If we get a good strategic investor for PCR Investments, we will look at it. But it will not be a significant dilution of our stake. The family will always remain in control of Apollo Hospitals in the health care delivery space.
What type of strategic partnership are you looking at?
We have created a lot of digital content in the medical education space; we are looking to grow. Education is an important space. But, more than that, we are invested in core health care. It is important to focus on fundamentals; our primary objective is to remain invested in Apollo Hospitals.
Will a strategic partner invest only in 13 nursing and two medical colleges in the education vertical, or also in Medskill and Medvarsity Online?
We are looking at various options. It is a little premature to say where the investment will be. The primary aim is to bring down our pledge over the next year. The strategic partnership could also help us grow the digital vertical, but I think our primary aim is to reduce the pledged shares.
The promoters’ pledged shares went up to 78 per cent earlier, but came down afterwards. How do you see the increase in pledged shares again?
We invested some money to fund solvency in the insurance business. Right now, AHEL is doing very well and I think what we are realising from Apollo Munich is also three times the return of what we have invested.
I think we have always invested in creating health care assets; our focus remains health care delivery. We are not looking at asset sales in the listed entity.
How much do you plan to raise from the strategic partner?
It is a little bit premature right now to talk about that or to say whether we are talking to some investors.